U.S. markets open in 3 hours 8 minutes
  • S&P Futures

    4,420.25
    -26.75 (-0.60%)
     
  • Dow Futures

    34,582.00
    -147.00 (-0.42%)
     
  • Nasdaq Futures

    15,033.00
    -119.00 (-0.79%)
     
  • Russell 2000 Futures

    1,815.70
    -10.60 (-0.58%)
     
  • Crude Oil

    88.72
    -0.94 (-1.05%)
     
  • Gold

    1,944.20
    -22.90 (-1.16%)
     
  • Silver

    23.48
    -0.36 (-1.51%)
     
  • EUR/USD

    1.0659
    -0.0008 (-0.07%)
     
  • 10-Yr Bond

    4.3490
    0.0000 (0.00%)
     
  • Vix

    15.86
    +0.72 (+4.76%)
     
  • GBP/USD

    1.2294
    -0.0052 (-0.42%)
     
  • USD/JPY

    147.9610
    -0.2360 (-0.16%)
     
  • Bitcoin USD

    26,726.09
    -254.73 (-0.94%)
     
  • CMC Crypto 200

    570.22
    -9.14 (-1.58%)
     
  • FTSE 100

    7,684.21
    -47.44 (-0.61%)
     
  • Nikkei 225

    32,571.03
    -452.75 (-1.37%)
     

Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Jefferies Healthcare Conference June 7-8, 2023

Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc.

MORRISTOWN, N.J., May 31, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will be participating in investor meetings at the Jefferies Healthcare Conference at the Marriott Marquis in New York City on June 7-8, 2023.

Meeting Details  
For investors attending the conference who wish to meet with the Intercept management team, please reach out to Nareg Sagherian at Intercept to check the team’s availability.

About Intercept  
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH) and severe alcohol-associated hepatitis (sAH). For more information, please visit www.interceptpharma.com or connect with the Company on Twitter and LinkedIn.

Contact  
For more information about Intercept, please contact:

Investor inquiries: investors@interceptpharma.com  
Media inquiries: media@interceptpharma.com